×
About 855 results

ALLMedicine™ Minimal Change Disease Center

Research & Reviews  325 results

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

May 20th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Kidney Biopsy Features Most Predictive of Clinical Outcomes in the Spectrum of Minimal ...
https://doi.org/10.1681/ASN.2021101396
Journal of the American Society of Nephrology : JASN; Zee J, Liu Q et. al.

May 18th, 2022 - Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most pr...

New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionn...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107780
Clinical and Experimental Nephrology; Nakagawa N, Maruyama S et. al.

May 16th, 2022 - Recent clinical reports indicate a correlation between new-onset and relapse of nephrotic syndrome (NS) following coronavirus 2019 (COVID-19) vaccination in patients with glomerular diseases. However, there are no reports of a nationwide survey on...

Minimal change disease associated with gastrointestinal stromal tumor accompanied by si...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996523
BMC Nephrology; Yu CY, Liu J et. al.

Apr 13th, 2022 - Minimal change disease (MCD) is a common cause of the nephrotic syndrome. Several studies have shown an increased incidence of cancer in patients with MCD. However, there are no reports on the association between MCD and gastrointestinal stromal t...

see more →

Guidelines  1 results

Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.
https://doi.org/10.1016/j.kint.2021.05.015
Kidney International; Rovin BH, Adler SG et. al.

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  7 results

A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
https://clinicaltrials.gov/ct2/show/NCT02639260

May 20th, 2022 - Background. ManNAc (N-acetyl D-mannosamine) is an uncharged monosaccharide that is the biologic precursor of N-acetyl neuraminic acid (Neu5Ac, sialic acid). Sialic acids are the negatively charged, terminal monosaccharides of carbohydrate chains t...

Thrombin Generation Assay to Assess Thrombotic Risk in Nephrotic Patients
https://clinicaltrials.gov/ct2/show/NCT05301829

Mar 31st, 2022 - Thrombin generation test will be performed prospectively in nephrotic patients with various diseases (Minimal Change Disease (MCD), Malignant Nephrosclerosis (MN), Focal Segmental GlomeruloSclerosis (FSGS), diabetic glomerulopathy…) at diagnosis, ...

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
https://clinicaltrials.gov/ct2/show/NCT04009668

Feb 2nd, 2022 - The researchers are testing adalimumab, a treatment which blocks tumor necrosis factor (TNF), to see if it changes levels of urine biomarker levels (TIMP1 and MCP1). The outcomes may help develop individualized treatment options for future patient...

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)
https://clinicaltrials.gov/ct2/show/NCT03949972

Nov 22nd, 2021 - Idiopathic Nephrotic Syndrome is characterized by proteinuria, volume retention, hyperlipidemia, hypoalbuminemia. As Minimal Change Disease (MCD) represents by far the most prevalent underlying diagnosis in children older than 1 year, a kidney bio...

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease
https://clinicaltrials.gov/ct2/show/NCT04369183

Dec 1st, 2020 - Various studies have been conducted to identify effective treatment strategies for primary focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) so far. In the light of these studies, corticosteroids and calcineurin inhibitors...

see more →

News  5 results

Nephrotic Syndrome Patients at High Risk of Kidney Failure, Vascular Problems
https://www.medscape.com/viewarticle/954056

Jul 1st, 2021 - NEW YORK (Reuters Health) - Adults with primary nephrotic syndrome (NS) had close to a 20 times greater risk of developing kidney failure and higher risks of several cardiovascular diseases and death compared to those without NS in a large analysi...

Rituximab for Nephrotic Syndrome in Kids: A Note of Caution
https://www.medscape.com/viewarticle/904069

Feb 24th, 2020 - First-line Therapy for Nephrotic Syndrome: A Comparison Idiopathic nephrotic syndrome is the most common disorder of glomerular function in pediatrics.[1] Approximately 40% of children diagnosed with idiopathic nephrotic syndrome will have a relap...

Continuous B-cell Depletion in Nephrotic Syndrome: Latest on Rituximab
https://www.medscape.com/viewarticle/909227

Feb 27th, 2019 - FR, SD, and SR Nephrotic Syndrome: A Therapeutic Challenge Nearly two decades into the 21st century and steroids remain the first-line agent for many glomerulonephritides. In particular, steroids continue to have a dominant therapeutic role in tre...

Management of Nephrotic Syndrome in Children
https://www.medscape.com/viewarticle/459180

Abstract and Introduction Abstract Idiopathic childhood nephrotic syndrome generally has a favorable long-term prognosis. Prompt administration of and improved guidelines for monitoring therapy have decreased morbidity and mortality. The treatment...

Nephrotic Syndrome and Vasculitis Following SARS-CoV-2 Vaccine
https://www.medscape.com/viewarticle/958098

The immunologic response following several varieties of vaccination (especially meningococcal C conjugate vaccines) has been described as a potential trigger for the development of nephrotic syndrome (NS).[1,2] Coronavirus disease 2019 (COVID-19) ...

see more →